Eugene P. Kadar
Pfizer (United States)(US)PRX Research
Publications by Year
Research Areas
Analytical Chemistry and Chromatography, SARS-CoV-2 and COVID-19 Research, Computational Drug Discovery Methods, Metabolomics and Mass Spectrometry Studies, COVID-19 Clinical Research Studies
Most-Cited Works
- → An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19(2021)1,855 cited
- → Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19(2021)288 cited
- → Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19(2020)159 cited
- → Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir(2022)153 cited
- → Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans(2022)113 cited
- → Rapid determination of the applicability of hydrophilic interaction chromatography utilizing ACD Labs Log D Suite: A bioanalytical application(2007)34 cited
- → Metabolism and Excretion of Nirmatrelvir in Humans Using Quantitative Fluorine Nuclear Magnetic Resonance Spectroscopy: A Novel Approach for Accelerating Drug Development(2022)32 cited
- → A Novel Milli-fluidic Liver Tissue Chip with Continuous Recirculation for Predictive Pharmacokinetics Applications(2023)30 cited
- → Preclinical Development of an anti-5T4 Antibody–Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice(2015)27 cited